Table 3.
Analyses of Pooled Hazard Ratios for PFS Outcomes by Subgroup.
| Variables | Study, No. (%) | Patients, No. | Pooled HR (95% CI) for immunotherapy vs SOC | P value for interaction | ||
|---|---|---|---|---|---|---|
| BMs | non-BMs | BMs | non-BMs | |||
| Overall | 10 | 603 | 4,571 | 0.68 (0.52–0.87) | 0.68 (0.56–0.82) | 0.78 |
| Tumor type | ||||||
| NSCLC | 8 (80) | 513 | 3,805 | 0.61 (0.46–0.79) | 0.67 (0.52–0.85) | 0.25 |
| SCLC | 2 (20) | 90 | 766 | 1.03 (0.66–1.61) | 0.72 (0.62–0.84) | 0.13 |
| Study design | ||||||
| immunotherapy vs SOC | 5 (50) | 330 | 2,563 | 0.71 (0.54–0.93) | 0.78 (0.59–1.02) | 0.25 |
| immunotherapy + SOC vs SOC | 5 (50) | 273 | 2,008 | 0.65 (0.40–1.06) | 0.60 (0.49–0.72) | 0.47 |
| Line of therapy | ||||||
| first-line | 7 (70) | 384 | 2,912 | 0.61 (0.43–0.87) | 0.59 (0.51–0.68) | 0.74 |
| second- or later-line | 3 (30) | 219 | 1,659 | 0.80 (0.58–1.10) | 0.95 (0.77–1.18) | 0.37 |
| Immunotherapy type | ||||||
| anti-PD-1 | 8 (80) | 489 | 3,490 | 0.61 (0.47–0.79) | 0.63 (0.53–0.75) | 0.61 |
| anti-PD-L1 | 2 (20) | 114 | 1,081 | 1.04 (0.66–1.63) | 0.94 (0.61–1.44) | 0.77 |
| BMs proportion | ||||||
| <10 | 4 (40) | 159 | 1,753 | 0.83 (0.51–1.37) | 0.73 (0.50–1.05) | 0.97 |
| ≥10 | 6 (60) | 444 | 2,818 | 0.62 (0.47–0.83) | 0.65 (0.52–0.80) | 0.70 |
NSCLC, non–small cell lung cancer; SCLC, small cell lung cancer; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1; SOC, standard of care chemotherapy; BMs, brain metastases; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.